Rhabdomyosarcoma: New Windows of Opportunity

Rhabdomyosarcoma: New Windows of Opportunity Philip P. Breitfeld, William H. Meyer Oncologist 2005; 10: 518-527 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in sarcomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Interpret the histologic findings of rhabdomyosarcoma and differentiate rhabdomyosarcoma from other small round cell neoplasms. Define the extent of disease using the Intergroup Rhabdomyosarcoma Study stage and group systems and apply these systems to predict prognosis. Discuss the multidisciplinary nature of therapy for rhabdomyosarcoma. Evaluate the most appropriate risk-based therapy alternatives for rhabdomyosarcoma. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Aug. 03, 2005 Most Recent Review: Aug. 03, 2005* Most Recent Update: Aug. 03, 2005 Date Credit Expires: Aug. 03, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.